Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
MWN-AI** Summary
Aclarion, Inc., a healthcare technology firm specializing in the identification of chronic low back pain, has been honored as a "Rising Star" in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards during the HLTH event. This accolade marks a significant achievement for Aclarion, which was selected from over 1,800 submissions, highlighting its innovative approach and clinical impact.
The award, accepted by Chief Strategy Officer Ryan Bond, celebrates emerging companies in the digital health sector that show exceptional potential. Bond expressed pride in the recognition, emphasizing Aclarion’s commitment to advancing noninvasive diagnostic tools that help physicians make informed treatment decisions for millions suffering from chronic low back pain globally. The company's proprietary Nociscan solution stands out as a first-of-its-kind Software as a Service (SaaS) platform that utilizes Magnetic Resonance Spectroscopy (MRS) to differentiate between painful and non-painful lumbar discs.
By transforming MRS signals into objective biomarkers linked to disc pain, Nociscan provides critical insights that enable personalized treatment plans, improving clinical outcomes for patients. With an estimated 266 million people worldwide living with chronic low back pain, Aclarion’s innovations aim to set a new standard in diagnostic accuracy. The Digital Health Hub Foundation Awards, which recognize digital innovations that enhance healthcare efficiency and equity, affirm Aclarion's role as a leader in driving meaningful change in the healthcare landscape.
This honor not only elevates Aclarion’s profile within the digital health community but also underscores the operational and clinical advancements the company is making through its groundbreaking technology. For more information about Aclarion and the Nociscan solution, visit their website or contact the company directly.
MWN-AI** Analysis
Aclarion, Inc. has garnered attention in the healthcare technology space with its recent recognition as a "Rising Star" at the 2025 Digital Health Hub Foundation: Digital Health Awards. This achievement marks a significant endorsement of Aclarion's Nociscan solution, which aims to revolutionize the diagnosis and treatment of chronic low back pain—a condition affecting an estimated 266 million people globally.
The award is particularly noteworthy considering the competitive landscape, as Aclarion was selected from over 1,800 submissions. This recognition not only solidifies Aclarion's position as an innovator in the clinical diagnostic device field but also underscores the efficacy and potential impact of its proprietary technology, which employs advanced AI algorithms and biomarkers to help physicians accurately identify painful lumbar discs.
From an investment perspective, Aclarion appears to be on an upward trajectory. The award signals to investors that the company is making strides in a promising healthcare niche, which is becoming increasingly relevant as more individuals seek non-invasive solutions to chronic pain. The endorsement from the Digital Health Hub may also enhance the company's credibility, potentially attracting collaborations with larger healthcare institutions and increasing market visibility.
With the healthcare sector's growing emphasis on personalized medicine, Aclarion's focus on developing objective, noninvasive diagnostic tools is timely. Investors should pay close attention to how the company plans to leverage this recognition to boost its market presence and engage healthcare providers. Furthermore, as the digital health industry continues to evolve, Aclarion's status as a Rising Star could lead to enhanced funding opportunities and partnerships.
In conclusion, Aclarion's recent accolades position it as a formidable player in the digital health arena. For investors looking for growth opportunities within innovative healthcare solutions, Aclarion merits consideration as it strides towards establishing Nociscan as a new standard in the market for chronic back pain diagnosis.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company previously announced it was selected as a finalist from more than 1,800 submissions
Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain
BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced it was named a Rising Star in the Clinical Diagnostic Device category during the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH .
The Digital Health Awards are held annually and celebrates advancements in the digital health industry. The Rising Star track highlights emerging digital health companies that show exceptional potential and clinical impact. Chief Strategy Officer Ryan Bond accepted the award on behalf of Aclarion, recognizing the company as a next-generation innovator making significant changes through technology for patients with chronic low back pain.
“It’s an incredible honor to be recognized as a Rising Star and to be part of the Digital Health Awards at HLTH ecosystem that is shaping the future of digital health,” said Ryan Bond, Chief Strategy Officer of Aclarion. “This award underscores our team’s commitment to advancing objective, noninvasive information that helps physicians ‘see pain’ and make better treatment decisions for the millions suffering from chronic low back pain worldwide.”
This recognition highlights the company's aim to make Nociscan the gold standard in identifying sources of low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine. By transforming MR spectroscopy signals into objective biomarkers demonstrated to be associated with disc pain, Nociscan provides actionable information that enables physicians to develop more personalized treatment plans for patients. An estimated 266 million people across the globe live with chronic low back pain.
The Digital Health Hub Foundation Awards honor organizations making strides in improving healthcare speed, efficiency and equity with their digital innovations. Being named a winner from a pool of more than 1,800 submissions reflects Aclarion’s commitment to driving meaningful change in the healthcare landscape.
To find a Nociscan center, view our site map here .
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/601ee985-6f9f-445a-8cf4-9fb68063cc33
FAQ**
How does Aclarion Inc. plan to leverage the recognition from the Digital Health Awards to enhance its market presence for Aclarion Inc. Warrant ACONW and expand the adoption of its Nociscan solution in chronic low back pain diagnosis?
Can Aclarion Inc. provide insights into its strategy for scaling operations and increasing the availability of Nociscan centers in light of the global demand for solutions addressing chronic low back pain and the potential implications for Aclarion Inc. Warrant ACONW?
What specific milestones does Aclarion Inc. aim to achieve in the regulatory and commercialization processes for Nociscan, and how might these milestones impact the valuation of Aclarion Inc. Warrant ACONW in the coming years?
Given the current competitive landscape in digital health, what unique challenges does Aclarion Inc. anticipate facing as it seeks to position Nociscan as the gold standard, and how might these challenges affect the performance of Aclarion Inc. Warrant ACONW?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. Warrant (NASDAQ: ACONW).
NASDAQ: ACONW
ACONW Trading
-12.45% G/L:
$0.0401 Last:
3,323 Volume:
$0.040101 Open:
